Biotech · Public company · Dallas, TX, US
CG Oncology, Inc.
Ticker CGON · SEC CIK 0001991792
Track this companyFree. Adds CG Oncology, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials93 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- CG0070 Adenovirus VectorPhase 3 · Transitional Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Control Arm: Quadruple ChoicePhase 3 · Transitional Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Cretostimogene GrenadenorepvecPhase 3 · Non Muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- n-dodecyl-B-D-maltosidePhase 3 · Non Muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- CG0070Phase 2 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- CG0070Phase 2 · Non Muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- Cretostimogene GrenadenorepvecPhase 2 · High-Risk Non-Muscle-Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- oncolytic adenovirus expressing GMCSFPhase 2 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab InjectionPhase 2 · Non Muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCPHASE2 · RECRUITING · started Sep 16, 2024ClinicalTrials.gov NCT06567743 · fetched Nov 12, 2026
- A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 14, 2023ClinicalTrials.gov NCT06111235 · fetched Nov 12, 2026
- Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinPHASE2 · COMPLETED · started Dec 8, 2020ClinicalTrials.gov NCT04387461 · fetched Nov 12, 2026
- Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 27, 2020ClinicalTrials.gov NCT04452591 · fetched Nov 12, 2026
- Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBCPHASE1 · COMPLETED · started Oct 26, 2020ClinicalTrials.gov NCT04610671 · fetched Nov 12, 2026
- Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG FailurePHASE2 · COMPLETED · started Jun 2, 2015ClinicalTrials.gov NCT02365818 · fetched Nov 12, 2026
- Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder CancerPHASE2_PHASE3 · TERMINATED · started Mar 1, 2014ClinicalTrials.gov NCT01438112 · fetched Nov 12, 2026
- Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder CancerPHASE2 · WITHDRAWN · started Mar 1, 2014ClinicalTrials.gov NCT02143804 · fetched Nov 12, 2026
- An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGAVAILABLEClinicalTrials.gov NCT06443944 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 13, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 13, 2026 · fetched Nov 12, 2026